references

References:

  • Witkamp R, Meijerink J. The endocannabinoid system: an emerging key player in inflammation. Curr Opin Clin Nutr Metab Care. 2014 Mar;17(2)
  • Russo EB. Potential synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-64.
  • Perry G. Fine, M.D. , Mark J. Rosenfeld, M.S., Ph.D The Endocannabinoid System, Cannabinoids, and Pain.  National Institue of Health 2013 Oct; 4(4)
  • Babson KA, Sottile J, Morabito D. Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9
  • Barrie, N., & Manolios, N. (2017). The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. European journal of rheumatology, 4(3), 210-218.
  • Izzo A.A., Coutts A.A. (2005) Cannabinoids and the Digestive Tract. In: Pertwee R.G. (eds) Cannabinoids. Handbook of Experimental Pharmacology, vol 168. Springer, Berlin, Heidelberg
  • Muccioli GG, Ruggieri MR, Schicho R , Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. U.S. National Institute of Health 2015;231:423-47
  • Alhamoruni A, Wright KL, Larvin M et al. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol. 2012 Apr; 165(8): 2598–26
  • Hampson AJ1, Grimaldi M, Lolic M et al, Neuroprotective antioxidants from Cannabinoids. Ann N Y Acad Sci. 2000; 899:274-82.
  • http://emedicine.medscape.com/article/1361971-overview
  • Campos AC, Fogaça MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, Sonego AB, Rodrigues NS, Galve-Roperh I, Guimarães FS. Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol.  Pharmacol. 2017 May 23;8:269.
  • Rey AA, Purrio M, Viveros MP, et al. Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission. Neuropsychopharmacology. 2012 Nov; 37(12): 2624–2634
  • Leach ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011 Nov; 72(5): 735–74
  • Lau BK, Cota D, Cristino L, et al. Endocannabinoid modulation of homeostatic and non-homeostatic feeding circuits. Neuropharmacology. 2017 Jun 1. pii: S0028-3908(17)30258-7
  • Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. Chem Biodivers ;4:1678–1692
  • https://scientificamerican.com/scicurious-brain/knocking-5-ht1a-down-to-bring-mood-up/
  • Juknat A, Pietr M, Kozela E. et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol in BV-2 microglial cells. Br J Pharmacol. 2012 Apr;165(8):2512-28.
  • Pertwee RG, Howlett AC, Abood ME et al. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.Pharmacol Rev. 2010 Dec;62(4):588-631
  • Resstel LB1 Tavares RF, Lisboa SF. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009 Jan;156(1):181-8
  • More, SV, Choi DK. Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Mol Neurodegener. 2015. 10: 17.
  • Elsohly MA, Slade D. Chemical constituents of hemp the complex mixture of natural cannabinoids. Life Sci. 2005;78:539– 548.
  • Hong-En; Li, Xiao; Zhao, You-Xing; Ferguson, David K.; Hueber, Francis; Bera, Subir; Wang, Yu-Fei; Zhao, Liang-Cheng; Liu, Chang-Jiang & Li, Cheng-Sin (December 2006), A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. Journal of Ethnopharmacology. 108 (3): 414–422
  • Campbell VA, Gowran A. Alzheimer’s disease; taking the edge off w cannabinoids? Br J Pharmacol.2007 Nov; 152(5): 655–66
  • Rajesh M, Mukhopadhyay P, Bátkai S. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010 Dec 14; 56(25): 2115–2125.
  • Kokona D, Georgiuo P, Kounenidakis M. et al. Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease. Neural Plast. 2016; 2016: 8373020.
  • Mukhopadhyay P, Raesh M, Pan H. et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress and cell death in nephropathy. Free Radic Biol Med. 2010 Feb 1; 48(3): 457–467
  • https://en.wikipedia.org/wiki/Hemp
  • Witkamp R, Meijerink J. The endocannabinoid system: an emerging key player in inflammation. Curr Opin Clin Nutr Metab Care. 2014 Mar;17(2)
  • Pfeil A, Oelzner P, Bornholdt K, Hansch A, Lehmann G, et al. (2013) Joint damage in rheumatoid arthritis: assessment of a new scoring method.Arthritis Res Ther 15: R27.
  • Perry G. Fine, M.D. , Mark J. Rosenfeld, M.S., Ph.D The Endocannabinoid System, Cannabinoids, and Pain.  National Institute of Health 2013 Oct; 4(4)